2 results
Approved WMOCompleted
• To estimate the difference in the efficacy and safety of RAD001 10 mg p.o. daily dose in combination with bevacizumab 10 mg/kg administered intravenously every two weeks for first-line treatment of patients with metastatic carcinoma of the kidney…
Approved WMOCompleted
To study pharmacokinetics of intravenously and intraperitoneally administered bevacizumab in patients with malignant ascites for whom there is no systemic anti-tumour treatment available.